CBP - Pioneering and developing Bi-targeting XDC technology
Pioneering and developing Bi-targeting XDC technology
CBP-1018-101
CBP-1018-101
An Open-Label, Non-randomized, Multinational, Multi-center Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1018 First in Patients with Advanced Solid Tumors